India’s “The Economic Times”: Other contender is a consortium of Indian Pharmaceuticals and US equity funds.
India’s “The Economic Times” reports that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) may be one of the two finalists in the tender for the generic business of Germany’s Merk KGaA (XETRA:MRK). The other finalist is a consortium of India’s Torrent Pharmaceuticals Ltd. (BSE: 500420) and US equity funds Fortress Investment Group and Greater Pacific Capital, after Mylan Laboratories Inc. (NYSE:MYL) and Iceland’s Actavis Group HF (IC:ACT) dropped out of the race
“The Economic Times” cites unconfirmed reports suggest that the acquisition of Merck’s generics business could be in excess of $5 billion.
Published by Globes [online], Israel business news - www.globes.co.il - on March 25, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007